<DOC>
	<DOCNO>NCT02962973</DOCNO>
	<brief_summary>The purpose clinical investigation evaluate safety performance Carmat Total Artificial Heart ( TAH ) patient suffer advanced heart failure require biventricular support . Each subject receive Carmat TAH follow primary secondary endpoint 6 month , subsequent follow-up period extend 2 year post implant . The result study used support CE mark application .</brief_summary>
	<brief_title>European Clinical Evaluation Carmat Total Artificial Heart</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Patient age : 18 75 year 2 . Inotrope dependent cardiac Index ( CI ) &lt; 2.2 L/min/m2 inotropes 3 . On Optimal Medical Management judge investigator base current Heart Failure practice guideline ( ESC/AHA ) 4 . Eligible biventricular Mechanical Circulatory Support accord ISHLT guideline mechanical circulatory support : 1 . Biventricular failure least two follow hemodynamic/ echocardiographic measurement imply right heart failure : RVEF ≤ 30 % RVSWI ≤ 0.25 mmHg/mL/m2 TAPSE ≤ 14mm RVtoLV enddiastolic diameter ratio &gt; 0.72 CVP &gt; 15 CVPtoPCWP ratio &gt; 0.63 Tricuspid insufficiency grade 4 2 . Treatmentrefractory recurrent sustain ventricular tachycardia ventricular fibrillation presence untreatable arrhythmogenic pathologic substrate 3 . Heart failure due restrictive constrictive physiology ( e.g. , hypertrophic cardiomyopathy , cardiac amyloidosis / senile infiltrative heart disease ) 5 . Not eligible transplant eligible age 55 year older expect wait time heart transplant exceed 12 month estimate physician . 6 . Anatomic compatibility confirm use 3D imaging ( CTscan ) 7 . Patient 's affiliation health care insurance 8 . Signed informed consent obtain 1 . Body Mass Index ( BMI ) &lt; 15 &gt; 47 2 . Existence ongoing nontemporary mechanical circulatory support 3 . Existence temporary mechanical circulatory support IABP 4 . History cardiac organ transplant 5 . Patients require cardiopulmonary resuscitation &gt; 30 minute within 14 day prior implant 6 . Known intolerance anticoagulant antiplatelet therapy 7 . Coagulopathy define platelet &lt; 100k/µl INR ≥ 1.5 due anticoagulant therapy 8 . Cerebrovascular accident &lt; 3 month symptomatic know &gt; 80 % carotid stenosis 9 . Known abdominal thoracic aortic aneurysm &gt; 5 cm 10 . Endorgan dysfunction per investigator judgment follow limited criterion : 1 . Total bilirubin &gt; 100 µmol/L ( 5,8 mg/dl ) cirrhosis evidence ultrasound , CTscan positive biopsy 2 . GFR &lt; 30ml/min/1.73m2 11 . History severe Chronic Obstructive Pulmonary Disease severe restrictive lung disease 12 . Recent blood stream infection ( &lt; = 7 day ) 13 . Documented amyloid lightchain ( AL amyloidosis ) 14 . Hemodynamically significant peripheral vascular disease accompany rest pain extremity ulceration 15 . Illness , heart disease , would limit survival le 1 year 16 . Irreversible cognitive dysfunction , psychosocial issue psychiatric disease , likely impair compliance study protocol TAH management 17 . Participation clinical investigation likely confound study result affect study 18 . Pregnancy breast feeding ( woman age childbearing show negative pregnancy test )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Advanced heart failure</keyword>
	<keyword>Total artificial heart</keyword>
</DOC>